Low-Intensity Focused Ultrasound for Depression
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this clinical trial is to learn about evaluate the safety, tolerability, and feasibility of MRI-guided LIFU targeting the sgACC in Veterans with post-traumatic brain injury depression. The main questions it aims to answer are:
1. the safety, tolerability, and feasibility of MRI-guided LIFU.
2. Evaluate preliminary antidepressant efficacy.
3. Characterize target engagement using multimodal neuroimaging and electrophysiology.
4. Identify imaging and electrophysiological biomarkers that predict treatment response.
5. Generate preliminary effect size estimates to support future multicenter clinical trials.
Who Is on the Research Team?
Mahendra Bhati, MD
Principal Investigator
Stanford University
Are You a Good Fit for This Trial?
This trial is for veterans who have depression after a traumatic brain injury. Participants should also have symptoms of post-traumatic stress disorder (PTSD).Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Low-Intensity Focused Ultrasound (LIFU)
Trial Overview
The study compares real low-intensity focused ultrasound (LIFU) treatment to a sham (inactive) version, both guided by MRI and aimed at a specific brain area linked to mood regulation.
How Is the Trial Designed?
2
Treatment groups
Active Control
Placebo Group
Participants receive active LIFU over 5 consecutive treatment days, with 5 sessions per day and 20 minutes per session
Participants receive sham LIFU over 5 consecutive treatment days, with 5 sessions per day and 20 minutes per session
Find a Clinic Near You
Who Is Running the Clinical Trial?
Stanford University
Lead Sponsor
VA Palo Alto Health Care System
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.